Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. - Wikidata - awgldk - TriplyDB

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

http://www.wikidata.org/entity/Q34414237

about

Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Emerging treatment options for patients with castration-resistant prostate cancer.Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.Targeted therapy for renal cell carcinoma: The next lap.In pursuit of new anti-angiogenic therapies for cancer treatment Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.The changing therapeutic landscape of castration-resistant prostate cancer.Vandetanib for the treatment of lung cancer.Advances in targeted therapeutic agents.Current and emerging treatments in the management of castration-resistant prostate cancer.Assessing the in vivo efficacy of biologic antiangiogenic therapies.Aflibercept in lung cancer.The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.Progress of molecular targeted therapies for advanced renal cell carcinoma.Aflibercept--a decoy VEGF receptor.Do anti-angiogenic cancer therapies increase risk of significant weight loss?The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.Which strategy after first-line therapy in advanced colorectal cancer?Evaluation of aflibercept in the treatment of metastatic colorectal cancer.Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.Antiangiogenesis therapy in the treatment of metastatic colorectal cancer.Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept.

P2860

Q26853604-A508991B-4B1E-44A9-9E1F-260AB84F52B5 Q30424925-83E0DE74-D713-4792-93EB-E62550DA4751 Q33423350-EB17C95E-4CB8-4E8C-82FA-8402EC1FA58D Q33958519-9E68A99D-5E00-46B7-9082-F42F759C0DFF Q34348270-0FC8B3F7-6BFD-43A1-AE15-16E7932376BD Q35640101-4D0453D7-C5FE-499D-A52F-AFD6C0C1A101 Q35938926-8FEFEAB3-5119-4A67-8257-47FDFB7C4161 Q36166846-CA53CBFA-ADC3-4D76-ABDA-72088539884F Q36205399-E4C1D9C1-3E0E-44E1-94D8-6C1B5B70DA0F Q36652690-3C394470-7B43-4D41-AC4C-ED532913E0FB Q36936900-0F8B9EFF-D96D-4650-A7B9-1CCDA75A8F7D Q37558971-300116B0-F394-45DE-BA79-64F799610B0A Q37702529-91D7BC9D-B71F-44A5-8811-F2EEAE72E770 Q37825180-37DB4D23-4DFF-4C89-89C0-FEF80B04F839 Q37827451-B6C6BA9E-335A-459D-959C-B9828C453D38 Q37913983-E3B6C863-790D-4DBF-9D2B-59DB6102635A Q38016190-3C7A7AFD-66A2-4A7D-AB6B-6670D2F7B2A0 Q38029122-E6E967B5-C4DB-4388-B94F-46727182ABD9 Q38030595-FC8D7431-D301-4E50-9CB9-FF6BC6C734DA Q38051013-01CC4158-A089-485B-98BC-C366EA8280AB Q38063939-80696B16-D455-4B83-AA02-197505BAD1DF Q38083816-77503A29-B150-4E21-8DF0-9858DF7F07B8 Q38114478-AF10974C-1D17-4156-915A-ED60C2081FD0 Q38149133-02554A79-7B23-4D52-B13D-DD564C20C9BD Q38180313-3763C48B-81AA-4E43-9BF0-FC1E1C4483BF Q38192670-D4A39081-2523-494C-B270-258375B50205 Q38209147-1BE049F3-B894-4D2B-B4B5-58D9E12F7D8F Q38235941-F0009109-DF5E-4D90-B24B-723288E7AC2D Q38242744-0B36C413-07E6-4941-9AE9-4344EB3D6965 Q38491102-DDD1B056-1B37-4008-B8C8-17BB39334D1B Q42402968-EDFB1041-EE89-460B-9743-C69172A9BA62 Q42775518-E3C53E82-54CA-4400-9787-3F2D9298C369

P2860

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors.

http://www.wikidata.org/entity/Q34414237

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@ast

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@en

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@nl

type

label

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@ast

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@en

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@nl

prefLabel

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@ast

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@en

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@nl

P1433

Q34414237-24C1C2DF-CFD7-4B2C-B5A3-FFFECA783549

P1476

Q34414237-5C525269-3AC6-4272-87C8-9E0598ED2A73

P2093

Q34414237-0F14E858-01BE-44FA-ABA8-387984363D8D

Q34414237-14E7090D-7022-4ECC-B1DE-62D2CBED28F5

Q34414237-2A880139-04D6-4413-B6F5-88D3AEAF259B

Q34414237-3DB6FE8C-61CC-4D44-BB91-348FA78B2BD0

Q34414237-4642FE10-BD95-4D5C-8F45-A498A7BAC551

Q34414237-5993C4F9-DE9B-418D-94F3-EBDE2FD7A557

Q34414237-721F8ACC-DF5B-46EF-8D90-CCA7FDA09A6C

Q34414237-8725F216-C8C1-4741-A9A3-7D15203CA438

Q34414237-A05EFCFB-9356-46EE-9BA4-83B683A3E210

Q34414237-B2975FF6-CE40-4563-9604-B30C337AA677

P2860

Q34414237-0AB6F2CB-25CA-4854-B1E7-680C73F2DE20

Q34414237-11755F07-F86E-48C6-8681-4B0463BB092F

Q34414237-1C5A23F3-C23D-4AD9-AE5A-4155B5CA960A

Q34414237-1DC1CAEF-DF8F-4C38-AECA-10C3CB3AAEB3

Q34414237-55D9BC83-8D9C-4DC1-97A1-7E5B22FB95DB

Q34414237-78E0BBA5-AA13-4B05-8EEE-8A3A7364CFD1

Q34414237-7C21CA41-848F-405F-B4BE-5AE2CB77AC84

Q34414237-7EA368C9-4C64-4505-94CD-817D91619EAD

Q34414237-906C058F-BA4D-4A6F-8540-5467E8DEA8D8

Q34414237-95B1B891-50DD-46A8-8617-61C593BC8839

P304

Q34414237-CDD31D50-7584-481A-BA4C-98359EAA8164

P31

Q34414237-60D31C71-142A-40C8-8A69-207E170768BC

P356

Q34414237-37A39FBA-AF81-4FD5-ADAB-E8D52D054A52

P407

Q34414237-2B2572F4-2649-4330-8F3C-75453B4E7900

P433

Q34414237-6B1FCEF9-5478-4BBB-B7E9-391E23EE0BF4

P478

Q34414237-E1FAF849-C2B7-40C0-A0DC-2B32F17B8F70

P50

Q34414237-232EA264-8FA4-44B7-BA6F-52212332E9D7

P577

Q34414237-E2657A05-424F-4B6E-976B-69A7F533024D

P698

Q34414237-8ADB764C-3E99-4095-8F30-2B1C66CBA252

P932

Q34414237-262F9BA8-B889-485E-87BA-EC7C38E8EBA6

P356

1078-0432.CCR-09-2103

P1433

Clinical Cancer Research

P1476

Phase 1 study of aflibercept a ...... ts with advanced solid tumors.

@en

P2093

Amanda Psyrri

http://www.w3.org/2001/XMLSchema#string

Carol Aghajanian

http://www.w3.org/2001/XMLSchema#string

David Mendelson

http://www.w3.org/2001/XMLSchema#string

David R Spriggs

http://www.w3.org/2001/XMLSchema#string

Jakob Dupont

http://www.w3.org/2001/XMLSchema#string

Jesse M Cedarbaum

http://www.w3.org/2001/XMLSchema#string

John Murren

http://www.w3.org/2001/XMLSchema#string

Lawrence Schwartz

http://www.w3.org/2001/XMLSchema#string

Michael Gordon

http://www.w3.org/2001/XMLSchema#string

Paul Sabbatini

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.

Use of single voided urine samples to estimate quantitative proteinuria.

VEGF is an essential molecule for glomerular structuring.

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade.

P304

358-366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2103

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Scott Gettinger

P577

2009-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20028764

http://www.w3.org/2001/XMLSchema#string

P932

4211604

http://www.w3.org/2001/XMLSchema#string